TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area under the concentration-time curve of dipyridamole in plasma at steady state (AUCss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of dipyridamole in plasma at steady state (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Inhibition of cyclooxygenase for acetylsalicylic acid (ASA), analyte thromboxane B2 (TXB2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Are Non Dippers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major Venous Access Site Closure-related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Energy expenditure on Exercise Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy expenditure on Sedentary Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substrate oxidation on Exercise Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substrate oxidation on Sedentary Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elbow Flexor Maximal Voluntary Contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PK parameters of Cortexolone 17α-propionate and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in TPO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of detection of Chlamydial rRNA and DNA after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of Stability Margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with SDB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type of SDB (central or obstructive)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Opioid Medication Prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Allergy status to milk and peanut
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in FACIT Fatigue Score at Week 24
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change From Baseline in FACIT Fatigue Score at Week 48
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change From Baseline in FACIT Fatigue Score at Week 72
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change From Baseline in FACIT Fatigue Score at Week 96
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Clinician Severity Rating on the Anxiety Disorders Interview Schedule for Children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full Epithelialization of the Wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capillary Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Complete Control Defined as no Vomiting and no Use of Rescue Medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Living status
Endpoint domain: Mortality/survival
Primary endpoint: Number of students joining the tobacco free program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain Level Postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Presenting With Pain in the Back of the Knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overtreatment of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inadequate treatment of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-bleaching hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactate to bicarbonate ratio difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in PD20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Oxycodone Tablets Used for Breakthrough Pain
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intensity of Pain: Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractures Fully Healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between SUV and Ki-67 index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favorable rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of seminal clusterin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-resolution manometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastrointestinal Quality of Life index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain and discomfort during scaling and root planning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bacteria change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of nature of the bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of magnitude of bacteremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: number of patients with candidiasis of the oropharynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: number of patients with hoarseness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two minute walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of adequate depth compression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration of abiraterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum concentration of abiraterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time 0 to the last measurable concentration of abiraterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HI antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of oral malodour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-rated Thermal Comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Glycosylated Hemoglobin (HbA1c [%])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-year Risk for Fatal Cardiovascular Disease (CVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in EASE Total Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Tolerated Dose (MTD) of Fludarabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to ready for discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of response signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Decision preference regarding PPI use
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Qualitative assessment of the antrum of the stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of Thrombotic Microangiopathy (TMA) manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentrations of paclitaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentrations of 6-α-hydroxypaclitaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentrations of 3'-p-hydroxypaclitaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sleep schedules
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in meal schedules
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Percentage of patients meeting the success criterion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent reduction in ABO blood group specific IgM serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ventricular rate less than 120 beats per min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Capillary Refill time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with Statin Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cumulated Dose of Oral Targeted Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Neutrophil Lymphocyte Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Analgesia Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Halitmetry results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance characteristics of AminoIndexTM biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cardiac remodeling evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: level of risk for neuro-cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Percentage Predicted Forced Expiratory Volume in One Second (FEV1%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Percentage Predicted Forced Vital Capacity (FVC%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Percentage Predicted Forced Mid-Expiratory Flow Rate (FEF25-75%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dietary protein requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Construct validity of Arabic ASQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concurrent validity with BSID-III scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of ASQ-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speed, agility and balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to drug therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD checklist
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Trauma Related Nightmare Survey
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Trauma Symptoms Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Immediate outcomes of emerging and re-emerging diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Anti-rhG-CSF Antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: level of total tau, phosphorylated tau and amyloid peptide in the CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in isoagglutinin titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Musical Ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving A Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of clinically significant device-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate in object recognition exceeding chance alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor assessment based on RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occurrence of Cardiovascular Death, Myocardial Infarction, Stroke, Urgent Revascularization, or Glycoprotein IIb/IIIa Inhibitor Bailout
Endpoint domain: Mortality/survival
Primary endpoint: Preoperative IG count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Preoperative IG percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Social Cognition
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: ASCVD health changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Days of abstinence from cigarettes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion (Percent) of Patients Using Supplemental Opioids
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Efficacy of atezolizumab with bevacizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Melasma area severity index (MASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: sensory threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who discontinue because of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Non-toxicity rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in patient reported outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in health care claims
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plasma choline concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Whole blood choline concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: improvement in smell
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain during meatus insertion of cystoscope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multi-organ failure
Endpoint domain: Mortality/survival
Primary endpoint: Successful delivery of investigational therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Toxicity profile of each dose level
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of patients who mount an immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with first clinically significant Disease Activity Score (DAS) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with first response to treatment according to EULAR response criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of any type of Adverse events related to Orencia
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Xe VDP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Retinal Detachments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Number of participants with adverse events (AEs) after an inhaled dose of PRS-060
Endpoint domain: Adverse events/effects
Primary endpoint: Change in forced expiratory volume 1-second (FEV1) as part of spirometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: GI perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: gut damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in total physical activity time (min/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total physical activity time (MET.min/week)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pattern of expression of CD56
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of missed appointments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Progression to MIBC
Endpoint domain: Mortality/survival
Primary endpoint: Incontinence Episode Frequency (IEF) Per 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: European Quality Questionnaire (euroq2)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life Scale in Alzheimer's Disease (QOL-AD)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Short Physical Performance Battery (SPPB)-Modified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Small-bowel mucosal morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Disease-free thyroid specific survival
Endpoint domain: Mortality/survival
Primary endpoint: Insulin like growth factors levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from Baseline Maximal Isometric Contraction Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline Peak Contraction Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline Maximal 10-s Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline Isokinetic Contraction Work
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Depression severity (PHQ 9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain severity (Brief Pain Inventory)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue severity (Modified Fatigue Impact Scale)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Efficacy of FTGC session
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Troponin value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percent loss of total body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percent loss of visceral fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in attention deficit hyperactivity disorder-rating scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of treatment-guiding pleural workup
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Major Cytogenetic Response (MCyR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Hematologic outcomes
Primary endpoint: Percentage of Participants With Complete, Major, and Overall Hematologic Response (CHR, MaHR, & OHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Hematologic outcomes
Primary endpoint: Composite of major adverse cardiac events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage change in Urine albumin-to-creatinine ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Spontaneous recovery or death
Endpoint domain: Mortality/survival
Primary endpoint: Acetylcholine esterase values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anxiety change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prenatal attachment change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Obsessive Compulsive Inventory
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plaque Assessment After 6 Weeks of Dentifrice Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Gingivitis Assessment After 6 Weeks of Dentifrice Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Plaque Assessment After 12 Weeks of Dentifrice Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Gingivitis Assessment After 12 Weeks of Dentifrice Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Cerebral and peripheral oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of pacemaker sensed geko™ pulses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of social ties elicited by a specific name generator
Endpoint domain: Life impact
Endpoint subdomain: Social functioning